Giorgina Mangano

TL;DR: Overall, the data indicate that bindarit is a good candidate for new therapies against prostate and breast tumorigenesis, with an action through impairment of inflammatory cell responses during formation of the tumor–stroma niche microenvironment.

TL;DR: The data support the use of inhibitors of MCP production in the treatment of arthritogenic alphavirus syndromes and suggest that bindarit may be useful in treating RRVD and other alphvirus-induced arthritis in humans.

TL;DR: The use of inhibition of synthesis as a potentially viable and selective approach to modify the chemokine system and report that in activated monocytes and endothelial cells, it selectively inhibits the production of the monocyte chemotactic protein subfamily of CC inflammatory chemokines.

TL;DR: AF3442 is a selective mPGES-1 inhibitor which reduced monocyte PGE(2) generation also in the presence of plasma proteins and did not translate into redirection of PGH( 2) metabolism towards other terminal PG synthases in monocytes.

TL;DR: It is demonstrated that bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipIDAemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointedimal macrophage content.